Keyword: Alnylam Pharmaceuticals
Alnylam's givosiran reduced the rate of porphyria attacks in patients with acute hepatic porphyria. The company will file a rolling NDA for givosiran in mid-2019.
Alnylam Pharmaceuticals and CAMP4 Therapeutics partner to focus on rare disease of the liver.
What can you expect from M&A, IPOs and VC raises in 2019? We spoke to execs at the J.P. Morgan Healthcare Conference this week to find out.
The 16-year R&D quest to get Onpattro on the market, the first-ever approval for a small interfering ribonucleic acid, saw it gain a lot of love when it was approved in the summer.
Vir Biotechnology has started trials of its gene-silencing drug for hepatitis B, the first candidate from its partnership with Alnylam Pharmaceuticals.
Intellia Therapeutics is developing a CRISPR-based treatment to edit the mutation that causes transthyretin amyloidosis.
Alnylam says it will have to wait for the final results of a phase 3 trial of acute hepatic porphyria drug givosiran before filing.
Akcea has its first FDA approval for hATTR therapy Tegsedi but will be burdened with a black box warning as it chases rival Alnylam.
The readout linked the ALAS1-targeted RNAi to a drop in urinary ALA, a biomarker Alnylam and the FDA think may predict clinical benefit.
Boehringer’s Corsico jumps to head dev at GSK; Kite’s Polverino takes CSO role at Zymeworks; and Kymera taps former Alnylam executive as CMO.
